205 related articles for article (PubMed ID: 28342444)
21. Structural basis for the activation of acid ceramidase.
Gebai A; Gorelik A; Li Z; Illes K; Nagar B
Nat Commun; 2018 Apr; 9(1):1621. PubMed ID: 29692406
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic hematopoietic cell transplantation in Farber disease.
Ehlert K; Levade T; Di Rocco M; Lanino E; Albert MH; Führer M; Jarisch A; Güngör T; Ayuk F; Vormoor J
J Inherit Metab Dis; 2019 Mar; 42(2):286-294. PubMed ID: 30815900
[TBL] [Abstract][Full Text] [Related]
23. Molecular analyses of novel ASAH1 mutations causing Farber lipogranulomatosis: analyses of exonic splicing enhancer inactivating mutation.
Bashyam MD; Chaudhary AK; Kiran M; Reddy V; Nagarajaram HA; Dalal A; Bashyam L; Suri D; Gupta A; Gupta N; Kabra M; Puri RD; RamaDevi R; Kapoor S; Danda S
Clin Genet; 2014 Dec; 86(6):530-8. PubMed ID: 24355074
[TBL] [Abstract][Full Text] [Related]
24. Generation of an induced pluripotent stem cell line (TRNDi030-A) from a patient with Farber disease carrying a homozygous p. Y36C (c. 107 A>G) mutation in ASAH1.
Brooks BM; Yeh CD; Beers J; Liu C; Cheng YS; Gorshkov K; Zou J; Zheng W; Chen CZ
Stem Cell Res; 2021 May; 53():102387. PubMed ID: 34088014
[TBL] [Abstract][Full Text] [Related]
25. Farber lipogranulomatosis type 1--late presentation and early death in a Croatian boy with a novel homozygous ASAH1 mutation.
Cvitanovic-Sojat L; Gjergja Juraski R; Sabourdy F; Fensom AH; Fumic K; Paschke E; Levade T
Eur J Paediatr Neurol; 2011 Mar; 15(2):171-3. PubMed ID: 20609603
[TBL] [Abstract][Full Text] [Related]
26. Disruption of sphingolipid metabolism augments ceramide-induced autophagy in preeclampsia.
Melland-Smith M; Ermini L; Chauvin S; Craig-Barnes H; Tagliaferro A; Todros T; Post M; Caniggia I
Autophagy; 2015 Apr; 11(4):653-69. PubMed ID: 25853898
[TBL] [Abstract][Full Text] [Related]
27. Development of an acid ceramidase activity-based probe.
Ouairy CM; Ferraz MJ; Boot RG; Baggelaar MP; van der Stelt M; Appelman M; van der Marel GA; Florea BI; Aerts JM; Overkleeft HS
Chem Commun (Camb); 2015 Apr; 51(28):6161-3. PubMed ID: 25748248
[TBL] [Abstract][Full Text] [Related]
28. C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease.
Cozma C; Iurașcu MI; Eichler S; Hovakimyan M; Brandau O; Zielke S; Böttcher T; Giese AK; Lukas J; Rolfs A
Sci Rep; 2017 Jul; 7(1):6149. PubMed ID: 28733637
[TBL] [Abstract][Full Text] [Related]
29. Skin inflammation and impaired adipogenesis in a mouse model of acid ceramidase deficiency.
Rybova J; Kuchar L; Sikora J; McKillop WM; Medin JA
J Inherit Metab Dis; 2022 Nov; 45(6):1175-1190. PubMed ID: 36083604
[TBL] [Abstract][Full Text] [Related]
30. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
Dworski S; Lu P; Khan A; Maranda B; Mitchell JJ; Parini R; Di Rocco M; Hugle B; Yoshimitsu M; Magnusson B; Makay B; Arslan N; Guelbert N; Ehlert K; Jarisch A; Gardner-Medwin J; Dagher R; Terreri MT; Lorenco CM; Barillas-Arias L; Tanpaiboon P; Solyom A; Norris JS; He X; Schuchman EH; Levade T; Medin JA
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):386-394. PubMed ID: 27915031
[TBL] [Abstract][Full Text] [Related]
31. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes.
Li CM; Park JH; Simonaro CM; He X; Gordon RE; Friedman AH; Ehleiter D; Paris F; Manova K; Hepbildikler S; Fuks Z; Sandhoff K; Kolesnick R; Schuchman EH
Genomics; 2002 Feb; 79(2):218-24. PubMed ID: 11829492
[TBL] [Abstract][Full Text] [Related]
32. Polyarticular Arthritis and Spinal Muscular Atrophy in Acid Ceramidase Deficiency.
Teoh HL; Solyom A; Schuchman EH; Mowat D; Roscioli T; Farrar M; Sampaio H
Pediatrics; 2016 Oct; 138(4):. PubMed ID: 27650050
[TBL] [Abstract][Full Text] [Related]
33. Spinal muscular atrophy associated with progressive myoclonus epilepsy.
Topaloglu H; Melki J
Epileptic Disord; 2016 Sep; 18(S2):128-134. PubMed ID: 27647482
[TBL] [Abstract][Full Text] [Related]
34. Spinal muscular atrophy and Farber disease due to ASAH1 variants: A case report.
Lee BH; Mongiovi P; Levade T; Marston B; Mountain J; Ciafaloni E
Am J Med Genet A; 2020 Oct; 182(10):2369-2371. PubMed ID: 32627310
[TBL] [Abstract][Full Text] [Related]
35. Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy.
Schuchman EH
Biochim Biophys Acta; 2016 Sep; 1862(9):1459-71. PubMed ID: 27155573
[TBL] [Abstract][Full Text] [Related]
36. A novel mutation in an atypical presentation of the rare infantile Farber disease.
Al Jasmi F
Brain Dev; 2012 Jun; 34(6):533-5. PubMed ID: 21982811
[TBL] [Abstract][Full Text] [Related]
37. ASAH1 variant causing a mild SMA phenotype with no myoclonic epilepsy: a clinical, biochemical and molecular study.
Filosto M; Aureli M; Castellotti B; Rinaldi F; Schiumarini D; Valsecchi M; Lualdi S; Mazzotti R; Pensato V; Rota S; Gellera C; Filocamo M; Padovani A
Eur J Hum Genet; 2016 Nov; 24(11):1578-1583. PubMed ID: 27026573
[TBL] [Abstract][Full Text] [Related]
38. [A case report of childhood Farber's disease and literature review].
Bao XH; Tian JM; Ji TY; Chang XZ
Zhonghua Er Ke Za Zhi; 2017 Jan; 55(1):54-58. PubMed ID: 28072961
[No Abstract] [Full Text] [Related]
39. The molecular medicine of acid ceramidase.
Frohbergh M; He X; Schuchman EH
Biol Chem; 2015 Jun; 396(6-7):759-65. PubMed ID: 25938220
[TBL] [Abstract][Full Text] [Related]
40. [Farber's lipogranulomatosis].
Koga M
Nihon Rinsho; 1995 Dec; 53(12):3009-13. PubMed ID: 8577050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
